Matching articles for "Treatment of chronic kidney disease"
Issue 1336 · April 19, 2010 Free
Correction: Ferumoxytol (Feraheme)

In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23) , the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1…

Med Lett Drugs Ther. 2010 Apr 19; 52(1336):32
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23) , the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Issue 1334 · March 22, 2010
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation

Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease.…

Med Lett Drugs Ther. 2010 Mar 22; 52(1334):23-13
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis